180 Life Sciences, Korro Bio, NuScale Power: Retail Investors Turn Most Bullish On These Stocks
Small-cap stocks like Korro Bio and NuScale Power are benefiting from the momentum generated by larger stocks.
Stocktwits·11mo ago
More News
Korro Bio Board Changes and Strategic Advisor Agreement
An announcement from Korro Bio (KRRO) is now available. David L. Lucchino resigned from our Board of Directors on August 26, 2024, but will stay co...
TipRanks Financial Blog·1y ago
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...
Benzinga·1y ago
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer...
Globe Newswire·1y ago
Piper Sandler Reiterates Overweight Rating for Korro Bio (NASDAQ:KRRO)
Piper Sandler restated their overweight rating on shares of Korro Bio (NASDAQ:KRRO - Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Piper Sandler currently has a...
Ticker Report·1y ago
We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St·1y ago
Korro Bio (NASDAQ:KRRO) Price Target Increased to $115.00 by Analysts at HC Wainwright
Korro Bio (NASDAQ:KRRO Free Report) had its price target lifted by HC Wainwright from $100.00 to $115.00 in a research note published on Thursday, Marketbeat Ratings reports. The firm...
Zolmax·1y ago
Korro Bio (NASDAQ:KRRO) Rating Reiterated by Piper Sandler
Korro Bio (NASDAQ:KRRO Get Free Report)s stock had its overweight rating restated by equities research analysts at Piper Sandler in a report issued on Wednesday, Benzinga...
Zolmax·1y ago
Korro Bio Earns Buy Rating on Promising RNA Editing Technology for AATD Treatment
Analyst Mitchell Kapoor of H.C. Wainwright maintained a Buy rating on Korro Bio (KRRO Research Report), boosting the price target to $115.00. Mit...
TipRanks Financial Blog·1y ago
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Demonstrated the versatility of Korro's RNA...